News / All News / Article

Penguin On-Site | Weiming Penguin & Tencent's Pharmaceutical AI Enablement Meeting Concludes at Tencent's Beijing Headquarters, Exploring New Paths for Industry Digital Upgrades

Article images may contain Chinese text.

Image

On the afternoon of September 19, 2025, the “Weiming Penguin & Tencent Meeting on AI-Powered Growth for Pharmaceutical Manufacturers and Business Scenarios for 2025 AI Product Upgrades,” jointly hosted by Weiming Penguin and Tencent, was successfully held at Tencent's Beijing headquarters building. Focusing on the deep integration of AI with pharmaceutical operations, the meeting brought together industry experts and company representatives to explore practical paths for pharmaceutical digital upgrades and help pharmaceutical companies harness AI to overcome growth challenges.


A Major Opening
Image

Image


Starting at 13:00 that day, guests checked in and then toured the exhibition hall in an orderly manner, getting an early taste of the innovative atmosphere created by the integration of technology and pharmaceuticals.

The meeting officially opened with welcoming remarks from Dr. Zou Xiaoliang, founder and CEO of Weiming Penguin. Dr. Zou previously worked at Tencent and has spent the subsequent decade as an entrepreneur, witnessing four stages in the internet's development. He reflected that the venue—Tencent's Beijing headquarters building, located near the headquarters of internet platforms such as Baidu and Sina—had witnessed three waves of internet transformation and now stands amid a fourth, the AI technology revolution. He hoped that visiting Tencent would allow participants to experience its culture and inspire reflection on and practical use of AI. He also proposed taking future meetings into universities, specifically Peking University, and wished everyone a productive second half of the year, expressing the hope that Weiming Penguin's events would leave something of value for the industry.

Image

Wang Wei, Tencent Cloud's Director of General SaaS Channels, delivered remarks welcoming participants to Tencent and discussing the deep ties between Weiming Penguin and Tencent. He emphasized the original purpose of jointly hosting the meeting and the important value of AI in empowering the pharmaceutical industry.

Image



Insightful Presentations
Image

The meeting was hosted by Agnes, a key account manager at Weiming Penguin.

Image

Following the opening remarks, Zhao Lianjie, head of presales for Tencent Cloud's Cloud Intelligence foundation model products, presented “Enterprise Practices for an AI Agent Development Platform.” He introduced Tencent's foundation model strategy, emphasizing its complete end-to-end capabilities and ability to empower others with its own best practices. He also outlined an overall architecture for building enterprise end-to-end foundation model capabilities and illustrated its applications in healthcare and pharmaceuticals, including appointment registration and medical consultations.

Image

Wu Ming, a senior architect at Tencent Lexiang, presented “Building a One-Stop Intelligent Knowledge Base for Pharmaceutical Companies: An Enterprise ‘Efficiency Nuclear Bomb.’” He analyzed why pharmaceutical companies need AI knowledge bases, explaining that AI can turn a document repository into a corporate brain and help build competitive barriers. He proposed four approaches to AI knowledge base development and introduced how Tencent Lexiang's intelligent knowledge management can help pharmaceutical companies build AI knowledge bases that put knowledge within easy reach.

Image

Figo, a solutions expert at Weiming Penguin, presented “Building Pharmaceutical Companies' Digital Capabilities,” including cases of the latest AI application scenarios in 2025. He highlighted four considerations for AI applications: focus on practical implementation scenarios, evaluate results before and after implementation, have customer success cases, and choose implementation methods according to need. He also listed six AI application scenarios for pharmaceutical companies: automated data auditing, sales forecasting automated data auditing, sales forecasting, online and offline price maintenance, intelligent customer service and health advisers, an intelligence center and public sentiment management, and AI role-play training and assessment.

Image

Viola, a solutions expert at Weiming Penguin, delivered a presentation titled “An AI Knowledge Base Lifecycle Management Framework.” She noted that DeepSeek had taken the lead in driving a major shift in knowledge management. She emphasized that getting knowledge management right is the first step for Weiming Penguin's AI work, shared hands-on experience with pharmaceutical digitalization, and explained the core elements of managing knowledge throughout its lifecycle: revitalizing corporate knowledge assets, making knowledge readily accessible, and improving business value and efficiency.

Image



Roundtable Forum
Image

The meeting concluded with a roundtable moderated by Tian Ying, co-founder and president of Weiming Penguin, on “In-Depth Applications and Innovative Practices of AI in Enabling Growth for Marketing Enterprises.” Four guests representing different functions participated: Xiang Song from China Resources Pharmaceutical Commercial, Kent from Weiming Penguin, Zhang Weijun, CIO of Besunyen, and Wu Ming from Tencent Cloud. The opening discussion noted the industry's focus on digitalization and AI in 2025, along with policies issued by relevant Chinese government departments to advance pharmaceutical companies' digital and intelligent transformation and implement the “AI Plus” initiative. The forum posed three questions covering the state of digital transformation at the guests' companies; problems, responses, and challenges during transformation; and digital strategy considerations and plans for the “AI Plus” field looking ahead to China's 15th Five-Year Plan period.

Image


The successful meeting not only created a platform for Weiming Penguin and Tencent to share technological resources, but also gave pharmaceutical companies an opportunity to engage directly with cutting-edge AI technologies and exchange practical experience. The two parties will continue to deepen their collaboration and bring further momentum to the pharmaceutical industry's digital upgrades.

2025318